albumin bound paclitaxel II (SYHX2011) / CSPC Pharma - LARVOL DELTA

Efficacy and safety of Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-blind Phase III study (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Metastases • New P2 trial • Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) (clinicaltrials.gov) - P3 | N=454 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Metastases • New P3 trial • Breast Cancer • Oncology • Solid Tumor